FDA expands nod of Eli Lilly’s Jaypirca for earlier CLL/SLL treatment

Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor

Imugene reports strong early results for Azer-cel in aggressive blood cancer trial

Citius Oncology's new therapy offers new hope for cutaneous T-cell lymphoma patients

LYMPHIR addresses a clear clinical need in a disease with limited treatment options

Biocon Biologics secures market entry date for Denosumab biosimilars in Europe, Rest of the World

The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025

LANXESS unveils next-gen biosecurity solutions for Indian poultry market at Poultry Expo

LANXESS Biosecurity Solutions aims to deliver “advanced disinfection and hygiene solutions to support Indian farmers in maintaining healthier and safer farm environments

Lung Cancer Canada and Boehringer Ingelheim team up to transform lung cancer detection

Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes

MHRA clears inavolisib, offering new option for returning breast cancer

The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy

India’s pharma industry showcases innovation, global ambitions at CPHI & PMEC India 2025

India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem

Novo Nordisk fast-tracks higher-dose obesity drug to FDA

The drug, intended for chronic weight management alongside diet and exercise, is now under the FDA’s new CNPV expedited review pathway

Cidara hits target enrollment for Phase 3 flu trial ahead of peak season

CD388 is administered as a single 450-milligram subcutaneous dose in adults and adolescents